CORRELATION OF CLINICAL-IMMUNOHISTOCHEMICAL WITH MOLECULAR CHARACTERISTICS IN EARLY BREAST CANCER

Authors

  • Ilir Kurtishi Oncology Clinic, University Clinical Center, Pristina, Kosovo
  • Violeta Klisarovska University Clinic for Radiotherapy and Oncology, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, Republic of North Macedonia
  • Snezana Smichkoska University Clinic for Radiotherapy and Oncology, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, Republic of North Macedonia
  • Brunilda Profka Haxhiu Oncology Clinic, University Clinical Center, Pristina, Kosovo
  • Fisnik Kurshumliu Oncology Clinic, University Clinical Center, Pristina, Kosovo
  • Ilir Ismaili University Clinic for Radiotherapy and Oncology, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, Republic of North Macedonia
  • Arben Bislimi Oncology Clinic, University Clinical Center, Pristina, Kosovo
  • Behar Raci Oncology Clinic, University Clinical Center, Pristina, Kosovo

Keywords:

BluePrint, early breast cancer, immunohistochemistry, MammaPrint, recurrence

Abstract

Introduction: In modern oncology, immunohistochemistry and genomic tests are two complementary approaches in the characterization of early breast cancer. Their combination better reflects the biological potential for growth and metastasis.

Material and methods: A total of 88 patients with early breast cancer were analyzed, classified according to immunohistochemistry and MammaPrint/BluePrint, after which a clinical correlation was made.

Results: Molecular typing with MammaPrint/BluePrint presented 42 patients (47.73%) with a high risk of recurrence. There was no statistically significant association with age (p=0.655), nodal status pN (p=0.113), or histological type of cancer (p=1.0). Patients with high and low risk differed significantly in terms of tumor size, i.e. by pT classification (p=0.0036), and G classification (p=0.0044).

Conclusion: Genomic profiling should complement, not replace, immunohistochemistry, as the combined approach allows for the most accurate assessment of risk, biology, and optimal therapeutic strategy for each patient with early breast cancer.

References

Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013; 24(9): 2206-2223. doi: 10.1093/annonc/mdt303.

Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000; 406(6797): 747-752. doi: 10.1038/35021093.

Cardoso F, van't Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, et al. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med 2016; 375(8): 717-729. doi: 10.1056/NEJMoa1602253.

Andre F, Ismaila N, Allison KH, Barlow WE, Collyar DE, Damodaran S, et al. Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update. J Clin Oncol 2022; 40(16): 1816-1837. doi: 10.1200/JCO.22.00069.

Piccart M, van 't Veer LJ, Poncet C, Lopes Cardozo JMN, Delaloge S, Pierga JY, et al. 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. Lancet Oncol 2021; 22(4): 476-488. doi: 10.1016/S1470-2045(21)00007-3.

Drukker CA, Bueno-de-Mesquita JM, Retèl VP, van Harten WH, van Tinteren H, Wesseling J, et al. A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study. Int J Cancer 2013; 133(4): 929-936. doi: 10.1002/ijc.28082.

National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology: Breast cancer V.5.2025.

Krijgsman O, Roepman P, Zwart W, Carroll JS, Tian S, de Snoo FA, et al. A diagnostic gene profile for molecular subtyping of breast cancer associated with treatment response. Breast Cancer Res Treat 2012; 133(1): 37-47. doi: 10.1007/s10549-011-1683-z.

Viale G, de Snoo FA, Slaets L, Bogaerts J, van 't Veer L, Rutgers EJ, et al. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trial. Breast Cancer Res Treat 2018; 167(1): 123-131. doi: 10.1007/s10549-017-4509-9.

Glu¨ck S, de Snoo F, Peeters J, Stork-Sloots L, Somlo G. Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy. Breast Cancer Res Treat 2013; 139(3): 759–767. doi: 10.1007/s10549-013-2572-4.

Nguyen B, Cusumano PG, Deck K, Kerlin D, Garcia AA, Barone JL, et al. Comparison of molecular subtyping with BluePrint, MammaPrint, and TargetPrint to local clinical subtyping in breast cancer patients. Ann Surg Oncol 2012; 19(10): 3257-3263. doi: 10.1245/s10434-012-2561-6.

Frédéric Rince. Results From EORTC’s MINDACT Study Addressed In ASCO’s Breast Cancer Guideline Focused Update - EORTC [Internet]. EORTC. 2017 [cited 2025 Mar 19]. Available from: https://www.eortc.org/blog/2017/07/18/results-from-eortcs-mindact-study-addressed-in-ascos-breast-cancer-guideline-focused-update.

510(k) Premarket Notification [Internet]. Fda.gov. 2020 [cited 2025 Mar 19].Available from:https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K201902.

Knauer M, Mook S, Rutgers EJ, Bender RA, Hauptmann M, van de Vijver MJ, et al. The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat 2010; 120(3): 655-661. doi: 10.1007/s10549-010-0814-2.

Downloads

Published

2026-03-24

Issue

Vol. 6 No. 1 (2026): Acad Med J

Section

Original Articles

License

Copyright (c) 2026 Ilir Kurtishi, Violeta Klisarovska, Snezana Smichkoska, Brunilda Profka Haxhiu, Fisnik Kurshumliu, Ilir Ismaili, Arben Bislimi, Behar Raci

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

This work is licensed under CC BY 4.0